Dr Erin Brazel Awarded Prestigious Fellowship

Dr Erin Brazel Awarded Prestigious Fellowship

Adelaide, Australia

GPN Vaccines is pleased to announce that Dr Erin Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.

The prestigious fellowship secured by Dr Erin Brazel will support research on bacterial vaccines in a collaboration between GPN Vaccines and the University of Adelaide.

The project will explore combination vaccines for ear infections using GPN Vaccines’ lead candidate, Gamma-PN.

Dr Brazel from the University of Adelaide’s Research Centre for Infectious Diseases said “I am incredibly grateful for the support of the Passe & Williams Memorial Foundation. More than 80 per cent of children will experience a middle ear infection by the time they are three years old. This fellowship will allow us to further develop this vaccine approach to target a broader range of bacteria responsible for ear infections”.

The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.

GPN Vaccines’ Chief Operating Officer Dr Lauren Giorgio said “Collaborations between industry and academia are so important for the rapid development and translation of new medicines. This project further strengthens our long and successful relationship with the University of Adelaide”.

About GPN Vaccines

GPN Vaccines is a public (unlisted) biotechnology company developing a vaccine against Streptococcus pneumoniae, which is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now more than 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 20 of them. GPN Vaccines’ product, called Gamma-PN, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.

Media contacts

Dr Erin Brazel, erin.brazel@adelaide.edu.au, +61 8 8313 7552

Dr Lauren Giorgio, lauren@gpnvaccines.com, +61 8 8313 4671

Protecting children and adults from the world’s foremost bacterial pathogen